Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileAnthony Zietman, M.D., M.B.,B.S.

TitleJenot W. and William U. Shipley Professor of Radiation Oncology
InstitutionMassachusetts General Hospital
DepartmentRadiation Oncology
AddressDept. of Radiation Medicine
Massachusetts General Hospital
Boston MA 02114
Phone617/726-8150
Fax617/726-3603
vCardDownload vCard (login for email)

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Xiang HF, Lu HM, Efstathiou JA, Zietman AL, Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys. 2017 Apr 13. PMID: 28407345.
    View in: PubMed
  2. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. 2017 Feb 08. PMID: 28189428.
    View in: PubMed
  3. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017 Mar 07; 62(5):1644-1660. PMID: 28166057.
    View in: PubMed
  4. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428. PMID: 28146658.
    View in: PubMed
  5. Underwood TS, Voog JC, Moteabbed M, Tang S, Soffen E, Cahlon O, Lu HM, Zietman AL, Efstathiou JA, Paganetti H. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017 Apr; 56(4):575-581. PMID: 28075206.
    View in: PubMed
  6. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 Jun; 71(6):952-960. PMID: 28081860.
    View in: PubMed
  7. Palma DA, Yom SS, Bennett KE, Corry J, Zietman AL. Introducing: The Red Journal Gray Zone. Int J Radiat Oncol Biol Phys. 2017 Jan 01; 97(1):1. PMID: 27979440.
    View in: PubMed
  8. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2016 Dec 28. PMID: 28040351.
    View in: PubMed
  9. Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. In Reply to Samaratunga et al. Int J Radiat Oncol Biol Phys. 2016 Dec 01; 96(5):1127-1128. PMID: 27869088.
    View in: PubMed
  10. Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 Mar 01; 97(3):450-461. PMID: 28011046.
    View in: PubMed
  11. Buscariollo DL, Drumm M, Niemierko A, Clayman RH, Galland-Girodet S, Rodin D, Feldman AS, M Dahl D, McGovern FJ, F Olumi A, Eidelman A, Shipley WU, Zietman AL, Efstathiou JA. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e125-e133. PMID: 28274403.
    View in: PubMed
  12. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 Dec 01; 96(5):1046-1053. PMID: 27745980.
    View in: PubMed
  13. Egevad L, Samaratunga H, Srigley JR, Delahunt B, Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. BJU Int. 2016 Sep; 118(3):E1-2. PMID: 27524719.
    View in: PubMed
  14. Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 Dec 01; 96(5):1028-1036. PMID: 27727064.
    View in: PubMed
  15. Roberts HJ, Zietman AL, Efstathiou JA. Painting Dose: The ART of Radiation. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4):722-728. PMID: 27788945.
    View in: PubMed
  16. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Aug 15. PMID: 27528718.
    View in: PubMed
  17. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4):770-777. PMID: 27663760.
    View in: PubMed
  18. Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. Eur Urol. 2017 Feb; 71(2):e54. PMID: 27452952.
    View in: PubMed
  19. Klein EA, Smith JA, Zietman AL, Dasgupta P, Catto J, Droller M, Millar S. Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology. 2016 Oct; 96:179. PMID: 27443466.
    View in: PubMed
  20. Zietman AL. The Red Journal's Top Downloads of 2015. Int J Radiat Oncol Biol Phys. 2016 Jul 01; 95(3):861-863. PMID: 27302501.
    View in: PubMed
  21. Falit BP, Pan HY, Smith BD, Alexander BM, Zietman AL. The Radiation Oncology Job Market: The Economics and Policy of Workforce Regulation. Int J Radiat Oncol Biol Phys. 2016 Nov 01; 96(3):501-10. PMID: 27681745.
    View in: PubMed
  22. De Bari B, Zietman AL, Poortmans P. Prostatectomy vs radiation therapy for prostate cancer: The (still) unsolved dilemma. Radiother Oncol. 2016 05; 119(2):368. PMID: 27267818.
    View in: PubMed
  23. Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, I Walsh E, Hill EM, Down L, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Davies CF, Ng SY, Neal DE, Hamdy FC, Albertsen P, Reid CM, Oxley J, McFarlane J, Robinson MC, Adolfsson J, Zietman A, Baum M, Koupparis A, Martin RM. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. Br J Cancer. 2016 Jun 28; 115(1):90-4. PMID: 27253172; PMCID: PMC4931376.
  24. Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. BJU Int. 2016 Jun; 117(6):849. PMID: 27173992.
    View in: PubMed
  25. Moteabbed M, Trofimov A, Sharp G, Wang Y, Zietman A, Efstathiou J, Lu H. SU-G-JeP4-09: Impact of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy for Prostate Cancer. Med Phys. 2016 Jun; 43(6):3683. PMID: 28046335.
    View in: PubMed
  26. Wallner PE, Gerdeman A, Willis JM, Zietman AL. The American Board of Radiology radiation oncology Maintenance of Certification Part 3 Modular Examination: Evaluation of the first administration. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):436-438. PMID: 27687188.
    View in: PubMed
  27. Zietman A, Smith J, Klein E, Droller MJ, Dasgupta P, Catto J. New Gleason grading system: Statement from the Editors of six journals. Urol Oncol. 2016 Jun; 34(6):253. PMID: 27155915.
    View in: PubMed
  28. Zietman AL. Particle Therapy at the "Tipping Point": An Introduction to the Red Journal's Special Edition. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):1-3. PMID: 27084615.
    View in: PubMed
  29. Zietman AL. Making Radiation Therapy for Prostate Cancer More Economical and More Convenient. J Clin Oncol. 2016 Jul 10; 34(20):2323-4. PMID: 27091711.
    View in: PubMed
  30. Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology. 2016 Jul; 93:1. PMID: 27015942.
    View in: PubMed
  31. Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol. 2016 Jul; 70(1):1. PMID: 27012550.
    View in: PubMed
  32. Verma V, Shah C, Lautenschlaeger T, Lin C, Beriwal S, Zhen W, Mehta MP, Zietman AL. International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties. Int J Radiat Oncol Biol Phys. 2016 Jul 15; 95(4):1102-6. PMID: 27209507.
    View in: PubMed
  33. Smith JA, Zietman A, Klein E, Droller MJ, Dasgupta P, Catto J, Smith JA. Stage Grouping. J Urol. 2016 Jun; 195(6):1723. PMID: 26995538.
    View in: PubMed
  34. Zietman AL, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Editorial Statement on Gleason Scoring for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Jul 15; 95(4):1092. PMID: 27354124.
    View in: PubMed
  35. Eyler CE, Zietman AL. A (relatively) risky business: the link between prostatic radiotherapy and second malignancies. BMJ. 2016 Mar 02; 352:i1073. PMID: 26935234; PMCID: PMC4775868.
  36. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):454-64. PMID: 27084660.
    View in: PubMed
  37. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):444-53. PMID: 26907917; PMCID: PMC4834287 [Available on 05/01/17].
  38. Lam KO, Lee AW, Choi CW, Sze HC, Zietman AL, Hopkins KI, Rosenblatt E. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1106-12. PMID: 27026314.
    View in: PubMed
  39. Paganetti H, Zietman A. Why Is Proton Beam Therapy So Controversial? J Am Coll Radiol. 2015 Dec; 12(12 Pt A):1318-9. PMID: 26653836.
    View in: PubMed
  40. Wu AJ, Vapiwala N, Chmura SJ, Das P, Decker RH, Terezakis SA, Zietman AL. Taking "the Game" Out of The Match: A Simple Proposal. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):945-8. PMID: 26581129.
    View in: PubMed
  41. Ngwa W, Ngoma T, Zietman A, Mayr N, Elzawawy A, Winningham TA, Balogun O, Enwerem-Bromson N, Ntizimira C, Olopade OI, Oluwole D, Odedina F, Williams M, Flanigan J, Asana L, Ngwa K, Avery S, Pollard JM, Roland T, Funwi-gabga N, Mbarika V, Hardenbergh P, Winkfield K, Pipman Y, Stefan C, Ngoma M, Mohammed S, Katz M, Erno S, Moni J, Fitzgerald T, Tonlaar N, Efstathiou J, Gierga D, Ayo C, Knaul F, Gospodarowicz M, Makrigiorgos GM, Nguyen PL. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9. PMID: 26867873; PMCID: PMC4959435.
  42. Gray PJ, Zietman AL. Dose-Escalated Radiotherapy for Prostate Cancer: Is the Sky the Limit? JAMA Oncol. 2015 Oct; 1(7):883-4. PMID: 26181340.
    View in: PubMed
  43. Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ, Souhami L, Dobelbower MC, Sandler HM, Shipley WU. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys. 2016 Jan 01; 94(1):67-74. PMID: 26700703; PMCID: PMC4690848 [Available on 01/01/17].
  44. Zietman A. The Red Journal's Top Downloads of 2014. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):4-6. PMID: 26279016.
    View in: PubMed
  45. Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84. PMID: 26276528.
    View in: PubMed
  46. Zietman A. Letters Regarding the TARGIT-A Trial: The Editor's Introduction. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):951-952. PMID: 26194661.
    View in: PubMed
  47. Lu-Yao GL, Kim S, Moore DF, Shih W, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL. Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study. Prostate Cancer Prostatic Dis. 2015 Dec; 18(4):317-24. PMID: 26101187.
    View in: PubMed
  48. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. TU-EF-304-05: Anterior Proton Beams for Prostate Treatments Lead to Substantial Elevations in Modeled RBE-Weighted Rectal Dose. Med Phys. 2015 Jun; 42(6):3615. PMID: 26128957.
    View in: PubMed
  49. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu H. SU-E-T-457: Impact of Interfractional Variations On Anterior Vs. Lateral-Field Proton Therapy of Prostate Cancer. Med Phys. 2015 Jun; 42(6):3439. PMID: 26128119.
    View in: PubMed
  50. Wallner PE, Steinberg ML, McBride WH, Hahn SM, Zietman AL. A fork in the road: choosing the path of relevance. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):214-6. PMID: 25968821.
    View in: PubMed
  51. Zietman AL. The Red Journal's Outstanding Reviewer Awards for 2014. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):204-5. PMID: 25968818.
    View in: PubMed
  52. Zietman AL. Fifty years from Paris: the remarkable story of the lymphomas. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):1-2. PMID: 25863746.
    View in: PubMed
  53. Gray PJ, Zietman AL. Androgen deprivation with radiotherapy: how long is long enough? Lancet Oncol. 2015 Mar; 16(3):244-6. PMID: 25702877.
    View in: PubMed
  54. Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015 Jan; 47(1):1-3. PMID: 25474525.
    View in: PubMed
  55. Holliday EB, Yang G, Jagsi R, Hoffman KE, Bennett KE, Grace C, Zietman AL. Fate of manuscripts rejected from the Red Journal. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):3-10. PMID: 25835616.
    View in: PubMed
  56. Zietman AL. In reply to Raju. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1261. PMID: 25539379.
    View in: PubMed
  57. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 01; 32(34):3801-9. PMID: 25366678; PMCID: PMC4239302 [Available on 12/01/15].
  58. Mell LK, Zietman AL. Introducing prospective manuscript review to address publication bias. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):729-32. PMID: 25585776.
    View in: PubMed
  59. Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch. 2014 Dec; 465(6):623-8. PMID: 25316188.
    View in: PubMed
  60. Zietman AL. Too much impact? Scientific journals and the "impact factor". Int J Radiat Oncol Biol Phys. 2014 Oct 01; 90(2):246-8. PMID: 25304783.
    View in: PubMed
  61. Mitin T, Zietman AL. Promise and pitfalls of heavy-particle therapy. J Clin Oncol. 2014 Sep 10; 32(26):2855-63. PMID: 25113772; PMCID: PMC4152713.
  62. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med. 2014 Oct; 138(10):1387-405. PMID: 25092589.
    View in: PubMed
  63. Jagsi R, Bennett KE, Griffith KA, DeCastro R, Grace C, Holliday E, Zietman AL. Attitudes toward blinding of peer review and perceptions of efficacy within a small biomedical specialty. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):940-6. PMID: 25035195.
    View in: PubMed
  64. Zietman A. The Red Journal's top downloads of 2013. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):937-9. PMID: 25035194.
    View in: PubMed
  65. Zietman A. Bringing radiation therapy to underserved nations: an increasingly global responsibility in an ever-shrinking world. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):440-2. PMID: 24929151.
    View in: PubMed
  66. Moteabbed M, Trofimov A, Testa M, Sharp G, Wang Y, Paganetti H, Zietman A, Efstathiou J, Lu H. SU-E-T-616: Comparison of Plan Dose Accuracy for Anterior Vs. Lateral Fields in Proton Therapy of Prostate Cancer. Med Phys. 2014 Jun; 41(6):369. PMID: 28037706.
    View in: PubMed
  67. Xiang H, Qureshi M, De Armas R, Hirsch A, Katz M, Nicholas B, Keohan S, Lu H, Efstathiou J, Zietman A, Willins J, Kachnic J. SU-E-J-150: Impact of Intrafractional Prostate Motion On the Accuracy and Efficiency of Prostate SBRT Delivery: A Retrospective Analysis of Prostate Tracking Log Files. Med Phys. 2014 Jun; 41(6):190-191. PMID: 28036665.
    View in: PubMed
  68. Talcott JA, Manola J, Chen RC, Clark JA, Kaplan I, D'Amico AV, Zietman AL. Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int. 2014 Oct; 114(4):511-6. PMID: 24112602.
    View in: PubMed
  69. Chen RC, Hamstra DA, Sandler HM, Zietman AL. Complications of prostate cancer treatment. Lancet Oncol. 2014 Apr; 15(4):e150. PMID: 24694635.
    View in: PubMed
  70. Zietman AL. In reply to Bauman. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1213. PMID: 24661676.
    View in: PubMed
  71. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56. PMID: 24661658.
    View in: PubMed
  72. Zietman AL. The Red Journal's outstanding reviewers of 2013. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):984-5. PMID: 24661649.
    View in: PubMed
  73. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martínez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):618-23. PMID: 24411190.
    View in: PubMed
  74. Zietman AL. In reply to Lee. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):236. PMID: 24475500.
    View in: PubMed
  75. Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):11-7. PMID: 24246724.
    View in: PubMed
  76. Zietman A. Reply to Carl J. Rossi's Comment on "Proton beam and prostate cancer: An evolving debate" by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338-42]. Rep Pract Oncol Radiother. 2013; 18(6):344. PMID: 24416577; PMCID: PMC3863286.
  77. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. PMID: 24225970.
    View in: PubMed
  78. Hoffman RM, Penson DF, Zietman AL, Barry MJ. Comparative effectiveness research in localized prostate cancer treatment. J Comp Eff Res. 2013 Nov; 2(6):583-93. PMID: 24236797.
    View in: PubMed
  79. Zietman AL. Falsification, fabrication, and plagiarism: the unholy trinity of scientific writing. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):225-7. PMID: 23958142.
    View in: PubMed
  80. Zietman A, Bennett KE. The four Rs of the Red Journal: a progress report from the new editorial team. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):7-9. PMID: 23920384.
    View in: PubMed
  81. Gray PJ, Shipley WU, Efstathiou JA, Zietman AL. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer. Curr Opin Urol. 2013 Sep; 23(5):429-34. PMID: 23851382.
    View in: PubMed
  82. Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder. N Engl J Med. 2013 Aug 15; 369(7):660-7. PMID: 23944304.
    View in: PubMed
  83. Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013 Aug; 11(8):952-60. PMID: 23946174.
    View in: PubMed
  84. Zietman A. In regard to Shah. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):597. PMID: 23773385.
    View in: PubMed
  85. Zietman A. Proton beam and prostate cancer: An evolving debate. Rep Pract Oncol Radiother. 2013 Jul 03; 18(6):338-42. PMID: 24416575; PMCID: PMC3863190.
  86. Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013 Aug; 14(9):863-72. PMID: 23823157; PMCID: PMC3955198.
  87. Zietman AL. The Red Journal's most downloaded articles of 2012. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):218-21. PMID: 23643376.
    View in: PubMed
  88. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early detection of prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):419-26. PMID: 23659877; PMCID: PMC4020420.
  89. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract. 2013 May; 9(3):e90-5. PMID: 23942508; PMCID: PMC3651578.
  90. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):546-53. PMID: 23561651.
    View in: PubMed
  91. Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Curr Urol Rep. 2013 Apr; 14(2):109-15. PMID: 23341373.
    View in: PubMed
  92. Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol. 2013 Apr; 23(2):109-14. PMID: 23473687; PMCID: PMC3595123.
  93. Wala J, Craft D, Paly J, Zietman A, Efstathiou J. Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning. Med Dosim. 2013; 38(3):298-303. PMID: 23540492.
    View in: PubMed
  94. Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Pract Radiat Oncol. 2013 Apr-Jun; 3(2 Suppl 1):S30. PMID: 24674542.
    View in: PubMed
  95. Zietman AL, Viani GA. RETRACTED: High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis Int J Radiat Oncol Biol Phys 2012;83:e619-e625. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):899. PMID: 23577347.
    View in: PubMed
  96. Efstathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer. 2013 Apr 02; 108(6):1225-30. PMID: 23481182; PMCID: PMC3619274.
  97. Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):311-6. PMID: 23474117.
    View in: PubMed
  98. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35. PMID: 23436283; PMCID: PMC3759976.
  99. Fedewa SA, Shipley WU, Lin CC, Virgo KS, Kibel AS, Kamat AM, Rosenberg JE, Jemal A, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol. 2013 Feb 20; 31(6_suppl):248. PMID: 28136792.
    View in: PubMed
  100. Paly JJ, Zietman AL, Nguyen PL, Beard C, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. PMID: 28137047.
    View in: PubMed
  101. Zietman A, Avilés A. Retraction notice. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):286. PMID: 23431565.
    View in: PubMed
  102. Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol. 2013 Jan; 106(1):64-8. PMID: 23321493.
    View in: PubMed
  103. Zietman A. The Red Journal's Outstanding Reviewer Awards for 2012. Int J Radiat Oncol Biol Phys. 2013 Jan 1; 85(1):1-2. PMID: 23236993.
    View in: PubMed
  104. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan; 189(1 Suppl):S2-S11. PMID: 23234625.
    View in: PubMed
  105. Elnahal SM, Kerstiens J, Helsper RS, Zietman AL, Johnstone PA. Proton beam therapy and accountable care: the challenges ahead. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):e165-72. PMID: 23265572.
    View in: PubMed
  106. Nassif D, Chen RC, Hoffman KE, Kuban DA, Lawton CA, Michalski JM, Potters L, Rose CM, Sandler HM, Suh W, Wall T, Zietman AL, Bekelman JE. National Radiation Oncology Registry: The pilot prostate cancer registry. J Clin Oncol. 2012 Dec; 30(34_suppl):267. PMID: 28147066.
    View in: PubMed
  107. Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013 May; 63(5):823-9. PMID: 23200811.
    View in: PubMed
  108. Zietman A. Top ten clinical research downloads of 2011. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):869-70. PMID: 23083912.
    View in: PubMed
  109. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. PMID: 22851571.
    View in: PubMed
  110. Zelefsky MJ, Cohen GN, Bosch WR, Morikawa L, Khalid N, Crozier CL, Lee WR, Zietman A, Owen J, Wilson JF, Devlin PM. Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy. Brachytherapy. 2013 Jan-Feb; 12(1):19-24. PMID: 22819388; PMCID: PMC3518616.
  111. Zietman A. The red journal's top 10 most downloaded articles of 2011. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1073-4. PMID: 22710025.
    View in: PubMed
  112. Wallner PE, Ang KK, Zietman AL, Harris JR, Ibbott GS, Mahoney MC, Mezwa DG, Wilson LD, Becker GJ. The American Board of Radiology Holman Research Pathway: 10-year retrospective review of the program and participant performance. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):29-34. PMID: 22682811.
    View in: PubMed
  113. Shipley WU, Zietman AL. Old drugs, new purpose--bladder cancer turning a corner. N Engl J Med. 2012 Apr 19; 366(16):1540-1. PMID: 22512487.
    View in: PubMed
  114. Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W, Gaffney D, Viswanathan AN, Michalski JM. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e353-62. PMID: 22483697; PMCID: PMC3904368.
  115. Kaufman DS, Zietman AL, McDougal WS, Dahl DM, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 9-2012. A 67-year-old man with a persistently elevated PSA level. N Engl J Med. 2012 Mar 22; 366(12):1143-50. PMID: 22435374.
    View in: PubMed
  116. Zelefsky MJ, Lee WR, Zietman A, Khalid N, Crozier C, Owen J, Wilson JF. Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey. Pract Radiat Oncol. 2013 Jan; 3(1):2-8. PMID: 23471563.
    View in: PubMed
  117. Efstathiou JA, Paly JJ, Lu HM, Athar BS, Moteabbed M, Niemierko A, Adams JA, Bekelman JE, Shipley WU, Zietman AL, Paganetti H. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012 Apr; 103(1):12-7. PMID: 22391053.
    View in: PubMed
  118. Shah A, Efstathiou JA, Paly JJ, Halpern SD, Bruner DW, Christodouleas JP, Coen JJ, Deville C, Vapiwala N, Shipley WU, Zietman AL, Hahn SM, Bekelman JE. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):e13-9. PMID: 22381899.
    View in: PubMed
  119. Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Virgo KS, Zietman AL. Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. J Clin Oncol. 2012 Feb 10; 30(5_suppl):272. PMID: 28143299.
    View in: PubMed
  120. Paly JJ, Efstathiou JA, Hedgire S, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Zietman AL, Shipley WU, Beard C. Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. J Clin Oncol. 2012 Feb 10; 30(5_suppl):324. PMID: 28143011.
    View in: PubMed
  121. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2012 Feb 10; 30(5_suppl):264. PMID: 28143313.
    View in: PubMed
  122. Aizer A, Paly JJ, Zietman AL, D'Amico AV, Nguyen PL, Beard C, Rao SK, Kaplan ID, Hirsch MS, Wu CL, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131. PMID: 28143227.
    View in: PubMed
  123. Gray PJ, Paly JJ, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen J, Shipley WU, Zietman AL, Bekelman JE, Efstathiou JA. Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):22. PMID: 28142916.
    View in: PubMed
  124. Gershman B, Zietman AL, Feldman AS, McDougal WS. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. Urol Oncol. 2013 Oct; 31(7):1093-7. PMID: 22305626.
    View in: PubMed
  125. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9. PMID: 22302227; PMCID: PMC3286170.
  126. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9. PMID: 22239226.
    View in: PubMed
  127. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan-Feb; 11(1):6-19. PMID: 22265434.
    View in: PubMed
  128. Zietman A, Ibbott G. A clinical approach to technology assessment: how do we and how should we choose the right treatment? Semin Radiat Oncol. 2012 Jan; 22(1):11-7. PMID: 22177874.
    View in: PubMed
  129. Zietman AL. Receiving the torch. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):1-2. PMID: 22182715.
    View in: PubMed
  130. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr; 61(4):705-11. PMID: 22101114.
    View in: PubMed
  131. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M, van Poppel H, Zietman A. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012 Mar; 61(3):443-51. PMID: 22036777.
    View in: PubMed
  132. Palta JR, Efstathiou JA, Bekelman JE, Mutic S, Bogardus CR, McNutt TR, Gabriel PE, Lawton CA, Zietman AL, Rose CM. Developing a national radiation oncology registry: From acorns to oaks. Pract Radiat Oncol. 2012 Jan-Mar; 2(1):10-7. PMID: 24674031.
    View in: PubMed
  133. Coen JJ, Paly JJ, Niemierko A, Weyman E, Rodrigues A, Shipley WU, Zietman AL, Talcott JA. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):e201-9. PMID: 21621343.
    View in: PubMed
  134. Smith MR, Zietman AL, Finkelstein JS, Wu CL. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer. N Engl J Med. 2011 May 26; 364(21):2044-51. PMID: 21612474.
    View in: PubMed
  135. Talcott JA, Zietman AL, Kaplan ID, Clark JA, D'Amico AV. Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4665. PMID: 28023888.
    View in: PubMed
  136. Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25. PMID: 24673925.
    View in: PubMed
  137. Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, Shipley WU. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e25-31. PMID: 21470787.
    View in: PubMed
  138. Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer. N Engl J Med. 2011 Feb 17; 364(7):667-75. PMID: 21323545.
    View in: PubMed
  139. Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu HM, Engelsman M, Merrick S, Cheng CW, Wong JR, Zietman AL. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):928-37. PMID: 20947266; PMCID: PMC3026870.
  140. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1005-9. PMID: 20932675.
    View in: PubMed
  141. Coen JJ, Feldman AS, Smith MR, Zietman AL. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int. 2011 May; 107(10):1582-6. PMID: 20860650; PMCID: PMC3082632.
  142. Eastham JA, Evans CP, Zietman A. What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol. 2010 Sep-Oct; 28(5):557-67. PMID: 20816616.
    View in: PubMed
  143. Zietman A, Goitein M, Tepper JE. Technology evolution: is it survival of the fittest? J Clin Oncol. 2010 Sep 20; 28(27):4275-9. PMID: 20697074.
    View in: PubMed
  144. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 2010 Jul; 96(1):6-12. PMID: 20400191.
    View in: PubMed
  145. Igdem S, Spiegel DY, Efstathiou J, Miller RC, Poortmans PM, Koca S, Kiliç-Unsal D, Okkan S, Zietman A. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study. Onkologie. 2010; 33(4):169-73. PMID: 20389142.
    View in: PubMed
  146. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010 Mar 17; 303(11):1046-53. PMID: 20233822.
    View in: PubMed
  147. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, Chakravarti A. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1095-103. PMID: 20231071; PMCID: PMC4348096.
  148. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22. PMID: 20346051; PMCID: PMC3090683.
  149. Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1081-5. PMID: 20207497.
    View in: PubMed
  150. Efstathiou JA, Shipley WU, Zietman AL, Smith MR. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol. 2010 Mar; 7(3):130-2. PMID: 20190794; PMCID: PMC2900769.
  151. Harrison LB, Zietman AL. American society for radiation oncology intersociety summit summary. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):643-8. PMID: 20159358.
    View in: PubMed
  152. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010 Mar 01; 28(7):1106-11. PMID: 20124169; PMCID: PMC2834463.
  153. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov; 182(5):2232-41. PMID: 19781717.
    View in: PubMed
  154. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA. 2009 Sep 16; 302(11):1202-9. PMID: 19755699; PMCID: PMC2822438.
  155. Zietman A. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. J Clin Oncol. 2009 Oct 20; 27(30):4935-6. PMID: 19720880.
    View in: PubMed
  156. Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009 Jul-Aug; 15(4):312-8. PMID: 19672148.
    View in: PubMed
  157. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging. 2009 Jul-Aug; 33(4):301-5. PMID: 19559353.
    View in: PubMed
  158. Lu-Yao G, Albertsen PC, Moore DF, Lin Y, Shih W, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, DiPaola RS, Yao S. Outcomes of conservatively managed localized prostate cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):5010. PMID: 27962906.
    View in: PubMed
  159. Coen JJ, Zietman AL. Proton radiation for localized prostate cancer. Nat Rev Urol. 2009 Jun; 6(6):324-30. PMID: 19434101.
    View in: PubMed
  160. Zietman A. Words of wisdom. Re: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Eur Urol. 2009 May; 55(5):1240. PMID: 19650206.
    View in: PubMed
  161. Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):361-8. PMID: 19394158; PMCID: PMC2847420.
  162. Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int. 2009 Jul; 104(2):179-83. PMID: 19154448.
    View in: PubMed
  163. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Tanguay S, Sandler HM. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009 Apr; 73(4):833-7. PMID: 19100600.
    View in: PubMed
  164. Mak RH, Zietman AL, Heney NM, Kaufman DS, Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int. 2008 Nov; 102(9 Pt B):1345-53. PMID: 19035903.
    View in: PubMed
  165. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):377-82. PMID: 18947941; PMCID: PMC2905162.
  166. Tripuraneni P, Watson RL, Ang KK, Harrison L, Eifel P, Zietman A, Haffty B, Thevenot LI, Willett CG, Schomberg PJ, Pickles T, Halberg FE, Devlin PM. Intersociety Radiation Oncology Summit-SCOPE II. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):323-6. PMID: 18793951.
    View in: PubMed
  167. Williams SG, Zietman AL. Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. World J Urol. 2008 Oct; 26(5):447-56. PMID: 18777126.
    View in: PubMed
  168. Wo JY, Zietman AL. Why does androgen deprivation enhance the results of radiation therapy? Urol Oncol. 2008 Sep-Oct; 26(5):522-9. PMID: 18774467.
    View in: PubMed
  169. Zietman A. The future of radiation oncology: the evolution, diversification, and survival of the specialty. Semin Radiat Oncol. 2008 Jul; 18(3):207-13. PMID: 18513631.
    View in: PubMed
  170. Nguyen PL, Trofimov A, Zietman AL. Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Williston Park). 2008 Jun; 22(7):748-54; discussion 754, 757. PMID: 18619120.
    View in: PubMed
  171. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213. PMID: 18502900; PMCID: PMC2900775.
  172. Talcott JA, Slater JD, Zietman A, Rossi C, Shipley WU, Clark JA. Long-term quality of life after conventional-dose versus high-dose radiation for prostate cancer: Results from a randomized trial (PROG 95-09). J Clin Oncol. 2008 May 20; 26(15_suppl):5058. PMID: 27948779.
    View in: PubMed
  173. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15; 112(10):2188-94. PMID: 18348297; PMCID: PMC2562782.
  174. Zietman A. Active surveillance: a safe, low-cost prognostic test for prostate cancer. BJU Int. 2008 May; 101(9):1059-60. PMID: 18325062.
    View in: PubMed
  175. Zietman AL. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA. 2008 Feb 27; 299(8):898-9. PMID: 18314431.
    View in: PubMed
  176. Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer. 2008 Feb 15; 112(4):943-9. PMID: 18098220.
    View in: PubMed
  177. Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1302-8. PMID: 18262732.
    View in: PubMed
  178. John SS, Zietman AL, Shipley WU, Harisinghani MG. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys. 2008; 71(1 Suppl):S43-7. PMID: 18406936.
    View in: PubMed
  179. Nguyen PL, Zietman AL. High-dose external beam radiation for localized prostate cancer: current status and future challenges. Cancer J. 2007 Sep-Oct; 13(5):295-301. PMID: 17921728.
    View in: PubMed
  180. Zietman AL. The Titanic and the Iceberg: prostate proton therapy and health care economics. J Clin Oncol. 2007 Aug 20; 25(24):3565-6. PMID: 17704400.
    View in: PubMed
  181. Kaufman DS, McDougal WS, Zietman AL, Young RH. Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer. N Engl J Med. 2007 Jun 14; 356(24):2515-20. PMID: 17568033.
    View in: PubMed
  182. Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, Delaney TF, Shipley WU. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):444-53. PMID: 17513063; PMCID: PMC2695934.
  183. Müller AC, Diestelhorst A, Kuhnt T, Kühn R, Fornara P, Scholz HJ, Dunst J, Zietman AL. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol. 2007 Apr; 183(4):177-83. PMID: 17406798.
    View in: PubMed
  184. Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol. 2007 Jan-Feb; 25(1):76-84. PMID: 17208144.
    View in: PubMed
  185. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar; 6(1):2-8. PMID: 17284379.
    View in: PubMed
  186. Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rödel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. Urology. 2007 Jan; 69(1 Suppl):80-92. PMID: 17280910.
    View in: PubMed
  187. Tsai HK, Katz MS, Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology. 2006 Dec; 68(6):1188-92. PMID: 17141846.
    View in: PubMed
  188. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006 Dec; 68(6):1257-62. PMID: 17141830.
    View in: PubMed
  189. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):327-33. PMID: 17084558.
    View in: PubMed
  190. Efstathiou JA, Zietman AL, Kaufman DS, Heney NM, Coen JJ, Shipley WU. Bladder-sparing approaches to invasive disease. World J Urol. 2006 Nov; 24(5):517-29. PMID: 17082940.
    View in: PubMed
  191. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006 Oct 01; 107(7):1496-502. PMID: 16944536.
    View in: PubMed
  192. Patrice SJ, Patrice JR, Steinberg JS, Zietman AL, Smith MR, Hayman JA. A cost-effectiveness analysis of surveillance, radiotherapy, and carboplatin in the management of stage I testicular seminoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6108. PMID: 27955226.
    View in: PubMed
  193. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006 Aug 01; 65(5):1487-93. PMID: 16750326.
    View in: PubMed
  194. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):975-81. PMID: 16750319.
    View in: PubMed
  195. Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005 Nov 15; 63(4):1262-9. PMID: 16253781.
    View in: PubMed
  196. Grocela J, Mauceri T, Zietman A. New life after prostate brachytherapy? Considering the fertile female partner of the brachytherapy patient. BJU Int. 2005 Oct; 96(6):781-2. PMID: 16153199.
    View in: PubMed
  197. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1140-50. PMID: 16198506.
    View in: PubMed
  198. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14; 294(10):1233-9. PMID: 16160131.
    View in: PubMed
  199. Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU, Chakravarti A. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005 Aug 01; 64(3):293-302. PMID: 15754318.
    View in: PubMed
  200. Zietman AL, Christodouleas JP, Shipley WU. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. Int J Radiat Oncol Biol Phys. 2005 Jul 01; 62(3):714-8. PMID: 15936550.
    View in: PubMed
  201. Talcott JA, Clark JA, Manola J, Zietman AL, Kaplan I, D'Amico AV, Coen J, Mitchell SP, Reilly CE. Using patient-reported outcomes to assess prostate brachytherapy technique. J Clin Oncol. 2005 Jun; 23(16_suppl):4697. PMID: 27946876.
    View in: PubMed
  202. Coen J, Bermudez S, Suzuki Y, Wu CL, Zhang M, Zietman A, Shipley W, Chakravarti A. VEGF-D expression predicts biochemical outcome in localized prostate cancer treated with external radiation: A ten-year cohort analysis. J Clin Oncol. 2005 Jun; 23(16_suppl):9660. PMID: 27943791.
    View in: PubMed
  203. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):795-9. PMID: 15925452.
    View in: PubMed
  204. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005 Mar; 173(3):797-802. PMID: 15711272.
    View in: PubMed
  205. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):415-9. PMID: 15667961.
    View in: PubMed
  206. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):409-14. PMID: 15667960.
    View in: PubMed
  207. Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol. 2005 Jan; 15(1):36-41. PMID: 15662605.
    View in: PubMed
  208. Zietman A, Skinner E. Quality of life after radical treatment for invasive bladder cancer. Semin Radiat Oncol. 2005 Jan; 15(1):55-9. PMID: 15662608.
    View in: PubMed
  209. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 2004 Oct; 172(4 Pt 1):1271-5. PMID: 15371822.
    View in: PubMed
  210. Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M, Hanks GE. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1053-61. PMID: 15234039.
    View in: PubMed
  211. Kaufman DS, McDougal WS, Zietman AL, Harisinghani MG, Young RH. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy. N Engl J Med. 2004 Jul 08; 351(2):171-8. PMID: 15247358.
    View in: PubMed
  212. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004 Jul 01; 22(13):2546-53. PMID: 15226323.
    View in: PubMed
  213. Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer. 2004 Feb 09; 90(3):578-81. PMID: 14760367; PMCID: PMC2409604.
  214. Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004 Jan; 171(1):210-4. PMID: 14665878.
    View in: PubMed
  215. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):915-28. PMID: 14575822.
    View in: PubMed
  216. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):929-43. PMID: 14575823.
    View in: PubMed
  217. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003 Nov 01; 57(3):665-72. PMID: 14529770.
    View in: PubMed
  218. Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003 Nov; 170(5):1772-6. PMID: 14532773.
    View in: PubMed
  219. Coen JJ, Chung CS, Shipley WU, Zietman AL. Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys. 2003 Nov 01; 57(3):621-8. PMID: 14529765.
    View in: PubMed
  220. Friedmann AM, Oliva E, Zietman AL, Aquino SL. Case records of the Massachusetts General Medicine. Weekly clinicopathological exercises. Case 9-2003. An 18-year-old man with back and leg pain and a nondiagnostic biopsy specimen. N Engl J Med. 2003 Mar 20; 348(12):1150-8. PMID: 12646672.
    View in: PubMed
  221. Sacco DE, Daller M, Grocela JA, Babayan RK, Zietman AL. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int. 2003 Mar; 91(4):345-9. PMID: 12603412.
    View in: PubMed
  222. Coen JJ, Zietman AL, Shipley WU. Prostatectomy or watchful waiting in prostate cancer. N Engl J Med. 2003 Jan 09; 348(2):170-1; author reply 170-1. PMID: 12523306.
    View in: PubMed
  223. Zietman AL. Dose escalation in localized prostate cancer: make no assumptions. Int J Radiat Oncol Biol Phys. 2002 Nov 01; 54(3):635-6. PMID: 12377310.
    View in: PubMed
  224. Zietman AL. Localized prostate cancer: brachytherapy. Curr Treat Options Oncol. 2002 Oct; 3(5):429-36. PMID: 12194807.
    View in: PubMed
  225. McNaughton Collins M, Barry MJ, Zietman A, Albertsen PC, Talcott JA, Walker Corkery E, Elliott DB, Fowler FJ. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology. 2002 Oct; 60(4):628-33. PMID: 12385923.
    View in: PubMed
  226. Yock TI, Zietman AL, Shipley WU, Thakral HK, Coen JJ. Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):420-6. PMID: 12243817.
    View in: PubMed
  227. Zietman A, Thakral H, Skowronski U, Shipley W. Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1152-9. PMID: 12128115.
    View in: PubMed
  228. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002 Aug 01; 20(15):3199-205. PMID: 12149291.
    View in: PubMed
  229. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002 Jul; 60(1):62-7; discussion 67-8. PMID: 12100923.
    View in: PubMed
  230. Chawla AK, Thakral HK, Zietman AL, Shipley WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology. 2002 May; 59(5):726-31. PMID: 11992848.
    View in: PubMed
  231. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb; 87(2):599-603. PMID: 11836291.
    View in: PubMed
  232. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002 Jan; 167(1):123-6. PMID: 11743288.
    View in: PubMed
  233. Zietman AL. Radiation, chemotherapy and transurethral surgery: an organ-sparing alternative to the radical cystectomy. Front Radiat Ther Oncol. 2002; 36:131-46. PMID: 11842743.
    View in: PubMed
  234. Zietman AL, Smith CT. Neoadjuvant androgen suppression and external beam radiation therapy. Front Radiat Ther Oncol. 2002; 36:87-98. PMID: 11842759.
    View in: PubMed
  235. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001 Nov; 166(5):1702-6. PMID: 11586206.
    View in: PubMed
  236. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27; 345(13):948-55. PMID: 11575286.
    View in: PubMed
  237. Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology. 2001 Sep; 58(3):380-5. PMID: 11549485.
    View in: PubMed
  238. Zietman A, Moughan J, Owen J, Hanks G. The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. Int J Radiat Oncol Biol Phys. 2001 May 01; 50(1):75-80. PMID: 11316549.
    View in: PubMed
  239. Brown AL, Zietman AL, Shipley WU, Kaufman DS. An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. Hematol Oncol Clin North Am. 2001 Apr; 15(2):345-58, vii. PMID: 11370497.
    View in: PubMed
  240. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J, Zietman A, Thompson I. Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. Urology. 2001 Feb; 57(2):217-24. PMID: 11182324.
    View in: PubMed
  241. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J, Zietman A, Thompson I. Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up. Urology. 2001 Feb; 57(2):225-9. PMID: 11182325.
    View in: PubMed
  242. Dunst J, Rödel C, Zietman A, Schrott KM, Sauer R, Shipley WU. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 2001 Jan-Feb; 20(1):24-32. PMID: 11291129.
    View in: PubMed
  243. Shipley WU, D'Amico AV, Zietman AL, Zietman A. Radiation oncology update. Urol Oncol. 2000 Dec 15; 6(1):29-30. PMID: 11113370.
    View in: PubMed
  244. Fowler FJ, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000 Jun 28; 283(24):3217-22. PMID: 10866869.
    View in: PubMed
  245. Chakravatri A, Zehr EM, Zietman AL, Shipley WU, Goggins WB, Finkelstein DM, Young RH, Chang EL, Wu CL. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. Urology. 2000 May; 55(5):635-8. PMID: 10792068.
    View in: PubMed
  246. Willett CG, Ooi CJ, Zietman AL, Menon V, Goldberg S, Sands BE, Podolsky DK. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys. 2000 Mar 01; 46(4):995-8. PMID: 10705022.
    View in: PubMed
  247. Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. Ann Med. 2000 Feb; 32(1):34-42. PMID: 10711576.
    View in: PubMed
  248. Zietman AL. The case for neoadjuvant androgen suppression before radiation therapy. Mol Urol. 2000; 4(3):203-8;discussion 215. PMID: 11062375.
    View in: PubMed
  249. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 1999 Aug; 162(2):445-50; discussion 450-1. PMID: 10411054.
    View in: PubMed
  250. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999 May 05; 281(17):1598-604. PMID: 10235152.
    View in: PubMed
  251. Zietman AL, Zehr EM, Shipley WU. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. Int J Radiat Oncol Biol Phys. 1999 Mar 01; 43(4):715-8. PMID: 10098425.
    View in: PubMed
  252. Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, Althausen AF, McGovern FJ. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol. 1998 Nov; 160(5):1673-7. PMID: 9783929.
    View in: PubMed
  253. Lazar AD, Winter MR, Nogueira CP, Larson PS, Finnemore EM, Dolan RW, Fuleihan N, Chakravarti A, Zietman A, Rosenberg CL. Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. Clin Cancer Res. 1998 Nov; 4(11):2787-93. PMID: 9829743.
    View in: PubMed
  254. Zietman A. Radioactive seeds for prostate cancer. Health News. 1998 Oct 25; 4(13):4-5. PMID: 9803172.
    View in: PubMed
  255. Vogelzang NJ, Crawford ED, Zietman A. Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel. Cancer. 1998 Jun 01; 82(11):2093-101. PMID: 9610688.
    View in: PubMed
  256. Zietman AL. Radiation therapy or prostatectomy: an old conflict revisited in the PSA era. A radiation oncologist's viewpoint. Semin Radiat Oncol. 1998 Apr; 8(2):81-6. PMID: 9516588.
    View in: PubMed
  257. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol. 1998; 33 Suppl 4:32-4. PMID: 9615208.
    View in: PubMed
  258. Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys. 1997 Nov 01; 39(4):937-43. PMID: 9369144.
    View in: PubMed
  259. Zietman AL, Westgeest JC, Shipley WU. Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):230-8. PMID: 9421450.
    View in: PubMed
  260. Kanady KE, Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer. Semin Surg Oncol. 1997 Sep-Oct; 13(5):359-64. PMID: 9259092.
    View in: PubMed
  261. Zietman AL, Shipley WU, Heney NM, Althausen AF. The case for radiotherapy with or without chemotherapy in high-risk superficial and muscle-invading bladder cancer. Semin Urol Oncol. 1997 Aug; 15(3):161-8. PMID: 9394911.
    View in: PubMed
  262. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997 Jul 15; 38(5):1067-70. PMID: 9276373.
    View in: PubMed
  263. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, Shipley WU. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Jul 01; 38(4):731-6. PMID: 9240639.
    View in: PubMed
  264. Zietman AL, Shipley WU. Progress in the management of T3-4 adenocarcinoma of the prostate. Eur J Cancer. 1997 Apr; 33(4):555-9. PMID: 9274434.
    View in: PubMed
  265. Powsner RA, Zietman AL, Foss FM. Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement. Clin Nucl Med. 1997 Mar; 22(3):147-50. PMID: 9067666.
    View in: PubMed
  266. Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, Shipley WU. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997 Mar; 15(3):1022-9. PMID: 9060542.
    View in: PubMed
  267. Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology. 1997 Mar; 49(3A Suppl):74-83. PMID: 9123741.
    View in: PubMed
  268. Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys. 1997 Jan 15; 37(2):245-6. PMID: 9069292.
    View in: PubMed
  269. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am. 1997 Jan-Feb; 3(1):31-6. PMID: 9072305.
    View in: PubMed
  270. Colvett KT, Althausen AF, Bassil B, Heney NM, McGovern FV, Young HH, Kaufman DS, Zietman AL, Shipley WU. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. J Surg Oncol. 1996 Nov; 63(3):201-8. PMID: 8944067.
    View in: PubMed
  271. Douglas RM, Kaufman DS, Zietman AL, Althausen AF, Heney NM, Shipley WU. Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol. 1996 Oct; 23(5):614-20. PMID: 8893872.
    View in: PubMed
  272. Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, Shipley WU. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1996 Aug; 40(2):159-62. PMID: 8884970.
    View in: PubMed
  273. Hartford AC, Zietman AL. Prostate cancer. Who is best benefited by external beam radiation therapy? Hematol Oncol Clin North Am. 1996 Jun; 10(3):595-610. PMID: 8773499.
    View in: PubMed
  274. Fagundes MA, Zietman AL, Althausen AF, Coen JJ, Shipley WU. The management of spermatic cord sarcoma. Cancer. 1996 May 01; 77(9):1873-6. PMID: 8646687.
    View in: PubMed
  275. Liu MC, Zietman AL, Shipley WU. Organ preservation approaches with radiation therapy in muscle-invasive bladder carcinoma. Ann Acad Med Singapore. 1996 May; 25(3):441-7. PMID: 8876914.
    View in: PubMed
  276. Edelstein RA, Zietman AL, de las Morenas A, Krane RJ, Babayan RK, Dallow KC, Traish A, Moreland RB. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology. 1996 Mar; 47(3):370-5. PMID: 8633404.
    View in: PubMed
  277. Kachnic LA, Shipley WU, Griffin PP, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. Cancer J Sci Am. 1996 Mar-Apr; 2(2):79-84. PMID: 9166504.
    View in: PubMed
  278. Zietman AL, Coen JJ, Ferry JA, Scully RE, Kaufman DS, McGovern FG. The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. J Urol. 1996 Mar; 155(3):943-6. PMID: 8583613.
    View in: PubMed
  279. Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology. 1996 Feb; 47(2):236-9. PMID: 8607241.
    View in: PubMed
  280. Zietman AL, Shipley WU, Kaufman DS, Esrig D, Lytton B. Point and counterpoint. Radical cystectomy or multimodality therapy for TCC of the bladder? Contemp Urol. 1995 Jul; 7(7):23-4, 29, 32, passim. PMID: 10150577.
    View in: PubMed
  281. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):287-92. PMID: 7751173.
    View in: PubMed
  282. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995 Apr 30; 32(1):3-12. PMID: 7721636.
    View in: PubMed
  283. Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J Urol. 1994 Nov; 152(5 Pt 2):1806-12. PMID: 7523726.
    View in: PubMed
  284. Shipley WU, Zietman AL, Hanks GE, Coen JJ, Caplan RJ, Won M, Zagars GK, Asbell SO. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol. 1994 Nov; 152(5 Pt 2):1799-805. PMID: 7933239.
    View in: PubMed
  285. Zietman AL, Shipley WU. Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol. 1994 Nov; 152(5 Pt 1):1564-5; author reply 1565-6. PMID: 7523713.
    View in: PubMed
  286. Zietman AL, Shipley WU. Organ-sparing treatment for bladder cancer: time to beat the drum. Int J Radiat Oncol Biol Phys. 1994 Oct 15; 30(3):741-2. PMID: 7928511.
    View in: PubMed
  287. Centeno BA, Zietman AL, Shipley WU, Sobczak ML, Shipley JW, Preffer FI, Boyle BJ, Colvin RB. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):309-15. PMID: 7928459.
    View in: PubMed
  288. Zietman AL. When should radiation therapy follow radical prostatectomy in the management of prostatic cancer? Mayo Clin Proc. 1994 Jul; 69(7):700-1. PMID: 7516989.
    View in: PubMed
  289. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 1994 Jun; 43(6):828-33. PMID: 7515206.
    View in: PubMed
  290. Willett CG, Zietman AL, Shipley WU, Coen JJ. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol. 1994 Jun; 151(6):1579-81. PMID: 7514692.
    View in: PubMed
  291. Gerweck LE, Zaidi ST, Zietman A. Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):57-66. PMID: 8175446.
    View in: PubMed
  292. Ferry JA, Harris NL, Young RH, Coen J, Zietman A, Scully RE. Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathologic study of 69 cases with immunophenotypic analysis. Am J Surg Pathol. 1994 Apr; 18(4):376-90. PMID: 8141430.
    View in: PubMed
  293. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 1994 Mar; 151(3):640-5. PMID: 7508522.
    View in: PubMed
  294. Nakfoor BM, Shipley WU, Zietman AL. Early stage testicular seminoma: the role of radiation therapy following orchiectomy. Front Radiat Ther Oncol. 1994; 28:183-95. PMID: 7982596.
    View in: PubMed
  295. Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer. 1993 Dec 01; 72(11):3156-73. PMID: 7694785.
    View in: PubMed
  296. Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Suit HD. Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res. 1993 Oct 15; 53(20):5018-21. PMID: 8402693.
    View in: PubMed
  297. Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Ruka W, Suit HD. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res. 1993 Oct 15; 53(20):5012-7. PMID: 8402692.
    View in: PubMed
  298. Zietman AL, Coen JJ, Shipley WU, Althausen AF. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology. 1993 Sep; 42(3):292-8; discussion 298-9. PMID: 7691014.
    View in: PubMed
  299. Zietman AL, Shipley WU, Kaufman DS. The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. Int J Radiat Oncol Biol Phys. 1993 Sep 01; 27(1):161-70. PMID: 8365937.
    View in: PubMed
  300. Zietman AL, Shipley WU. Randomized Trials in Loco-Regionally Confined Prostate Cancer: Past, Present, and Future. Semin Radiat Oncol. 1993 Jul; 3(3):210-220. PMID: 10717072.
    View in: PubMed
  301. Zietman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer. 1993 Feb 01; 71(3 Suppl):959-69. PMID: 7679046.
    View in: PubMed
  302. Zietman AL, Linggood RM, Brookes AR, Convery K, Piro A. Radiation therapy in the management of early stage Hodgkin's disease presenting in later life. Cancer. 1991 Nov 01; 68(9):1869-73. PMID: 1913538.
    View in: PubMed
  303. Zietman AL, Sugiyama E, Ramsay JR, Silobrcic V, Yeh ET, Sedlacek RS, Suit HD. A comparative study on the xenotransplantability of human solid tumors into mice with different genetic immune deficiencies. Int J Cancer. 1991 Mar 12; 47(5):755-9. PMID: 2004856.
    View in: PubMed
  304. Zietman AL, Suit HD, Okunieff PG, Donnelly SM, Dieman S, Webster S. The life shortening effects of treatment with doxorubicin and/or local irradiation on a cohort of young C3Hf/Sed mice. Eur J Cancer. 1991; 27(6):778-81. PMID: 1829923.
    View in: PubMed
  305. Okunieff P, Greenberg MD, Zietman A, Kahn J, Westgate S, Neuringer LJ. Failure of 1H nuclear magnetic resonance spectroscopy of blood plasma to detect malignancy. J Clin Oncol. 1990 May; 8(5):906-10. PMID: 2332773.
    View in: PubMed
  306. Okunieff P, Zietman A, Kahn J, Singer S, Neuringer LJ, Levine RA, Evans FE. Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med. 1990 Apr 05; 322(14):953-8. PMID: 2314447.
    View in: PubMed
  307. Miralbell R, Zietman A, Okunieff P, Thames HD, Suit HD. Fractionation sensitivity and immunological status in radiation treated murine sarcomas. Int J Radiat Oncol Biol Phys. 1990 Apr; 18(4):867-72. PMID: 2323974.
    View in: PubMed
  308. Zietman AL, Suit HD, Tomkinson KN, Thames HD, Sedlacek RS. The response of two human tumor xenografts to fractionated irradiation. The derivation of alpha/beta ratios from growth delay, tumor control, and in vitro cell survival assays. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):569-75. PMID: 2318689.
    View in: PubMed
  309. Silobrcic V, Zietman AL, Ramsay JR, Suit HD, Sedlacek RS. Residual immunity of athymic NCr/Sed nude mice and the xenotransplantation of human tumors. Int J Cancer. 1990 Feb 15; 45(2):325-33. PMID: 2406204.
    View in: PubMed
  310. Suit HD, Zietman A, Tomkinson K, Ramsay J, Gerweck L, Sedlacek R. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys. 1990 Feb; 18(2):365-73. PMID: 2154419.
    View in: PubMed
  311. Ramsay J, Zietman A, Preffer F, Suit HD. The growth and cell kinetics of a secondary tumor after radiation or surgical treatment of the primary tumor. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):809-13. PMID: 2777671.
    View in: PubMed
  312. Lauk S, Zietman A, Skates S, Fabian R, Suit HD. Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. Cancer Res. 1989 Aug 15; 49(16):4557-61. PMID: 2743340.
    View in: PubMed
  313. Zietman AL, Suit HD, Ramsay JR, Silobrcic V, Sedlacek RS. Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr/Sed nude mice. Cancer Res. 1988 Nov 15; 48(22):6510-6. PMID: 3052803.
    View in: PubMed
  314. Suit HD, Sedlacek RS, Zietman A. Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. Cancer Res. 1988 Aug 15; 48(16):4525-8. PMID: 3293775.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Zietman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_